1. Scrip
  2. >>COVID-19

Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study

 
• By Scrip Team

Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.    

Doctor, nurse, scientist hand in blue gloves holding flu, measles, coronavirus, covid-19 vaccine disease preparing for child, baby, adult, man and woman vaccination shot, medicine and drug concept.
• Source: Shutterstock

AstraZeneca PLC said on 23 October that the US Food and Drug Administration authorized the company to restart its clinical trials for the adenovirus-based vaccine AZD1222 for the prevention of infection with the SARS-CoV-2 virus. Trials were paused globally on 6 September after a vaccinated study participant in the UK developed serious spinal inflammation known as transverse myelitis; the US was the last country to allow testing of AZD1222 to resume.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

Stock Watch: Q3, Bonfire Of The Vaccine Manufacturers

 
• By Andy Smith

Pfizer’s and Moderna’s quarterly pandemic-related product sales could not mask other weaknesses while GSK’s quarter was marred by unimpressive non-pandemic vaccines sales.

Meiji Considers Legal Action Amid Japan Misinformation On Kostaive Vaccine

 
• By Lisa Takagi

Japanese distributor Meiji Seika Pharma is considering possible legal action against what it views as online slander around COVID-19 vaccine Kostaive, which received its global-first approval in Japan last year and has now been launched for regular vaccination in the country.

More from Scrip

Merck KGaA Moves Closer To Sealing SpringWorks Buy

 
• By Kevin Grogan

The German group could pay $3.5bn to get hold of the US firm and its two approved products.

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.